Stem cells in subclinical hypothyroidism

The role of circulating endothelial progenitor cells in relation to endothelial dysfunction in subclinical and overt hypothyroidism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN70334066

Enrollment

Registered

2009-09-16

Start date

2007-05-01

Completion date

Unknown

Last updated

2022-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypothyroidism Nutritional, Metabolic, Endocrine Other hypothyroidism

Interventions

Thyroxine dose 100 mcg (open label tablet) per day, dose adjusted if required.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Both males and females, age less than 70 2. Patients with confirmed subclinical hypothyroidism (thyroid-stimulating hormone [TSH]10 mU/L)

Exclusion criteria

Exclusion criteria: 1. Treatment for thyroid conditions 2. Known cardiovascular disease or risk factors

Design outcomes

Primary

Measure	Time frame
Number and function of endothelial progenitor cells. All outcomes will be assessed before and after thyroxine therapy (being stable for 3 months on therapy).	—

Secondary

Measure	Time frame
Flow mediated dilatation. All outcomes will be assessed before and after thyroxine therapy (being stable for 3 months on therapy).	—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 11, 2026